Additionally, BI-3406 has arisen as a promising alternative showing high specificity in inhibiting CRC cell growth harbouring KRAS mutations, especially in combination therapy with MEK inhibitors [129]. This evidence concerns the gene KRAS and colorectal carcinoma.